secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-022604
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M
--------------------------------------------------------------------------------

- Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.
- CyPath Lung testing revenue increased 122% YoY; test volumes up 97% in first nine months of 2025.
- Net loss $5.1M ($4.74 per share) compared to $2.0M loss ($4.84 per share) in Q3 2024, driven by change in fair value of warrants.
- Raised $10.4M gross proceeds from equity transactions; cash and equivalents increased to $7.7M from $1.1M at year-end 2024.
- Appointed Roberto Rios and John J. Oppenheimer to board; regained full Nasdaq compliance for listing of BIAF and BIAFW.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/0001493152-25-022604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315225022604/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer